- Home
- GILD vs TJX Comparison
GILD vs TJX Comparison
Compare GILD & TJX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILD | TJX |
|---|---|---|
| Founded | 1987 | 1962 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Clothing/Shoe/Accessory Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.0B | 173.8B |
| IPO Year | 2003 | 1994 |
Fundamental Metrics
Financial Performance| Metric | GILD | TJX |
|---|---|---|
| Price | $148.71 | $139.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 16 |
| Target Price | $148.39 | ★ $169.00 |
| AVG Volume (30 Days) | ★ 6.4M | 4.6M |
| Earning Date | 05-07-2026 | 05-20-2026 |
| Dividend Yield | ★ 2.55% | 1.23% |
| EPS Growth | ★ 1684.21 | 14.32 |
| EPS | N/A | ★ 1.19 |
| Revenue | $24,689,000,000.00 | ★ $29,078,407,000.00 |
| Revenue This Year | $4.68 | $6.75 |
| Revenue Next Year | $6.04 | $5.81 |
| P/E Ratio | ★ N/A | $118.25 |
| Revenue Growth | ★ 9.98 | 6.04 |
| 52 Week Low | $108.46 | $135.90 |
| 52 Week High | $157.29 | $170.00 |
Technical Indicators
Market Signals| Indicator | GILD | TJX |
|---|---|---|
| Relative Strength Index (RSI) | 68.47 | 26.79 |
| Support Level | $142.93 | N/A |
| Resistance Level | $149.38 | $157.27 |
| Average True Range (ATR) | 3.50 | 3.06 |
| MACD | 1.12 | -1.76 |
| Stochastic Oscillator | 91.85 | 7.89 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About TJX TJX Companies Inc. (The)
Founded in 1987, TJX Companies is the world's largest off-price apparel and home fashions retailer, operating more than 5,000 stores across nine countries. In fiscal 2026, the company generated roughly $60 billion in sales. TJX operates through four segments: Marmaxx (61% of sales), HomeGoods (17%), TJX Canada (9%), and TJX international (13%). Its off-price model emphasizes branded merchandise at meaningful discounts, driving high traffic and rapid inventory turnover.